LAG3 and glioblastoma: An antibody directed to LAG3 is in clinical trial combined with nivolumab for the treatment of glioblastoma (NCT02658981) while the antagonist LAG-3 mAb (LAG525) is in a phase I/II study as a combination treatment with PD-1 inhibition in solid tumors (NCT02460224).